drugset / Trial / NCT00004731

Parkinson's Disease Treatment With Coenzyme Q10

NCT00004731

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the effects of varying dosage of coenzyme Q10 (CoQ10) versus a placebo in the treatment of Parkinson's disease (PD) in patients with early, untreated PD.

Timeline

Start
1998-09
Primary completion
Completion
2003-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Coenzyme Q10 Other / unclassified 300 mg
Subject Coenzyme Q10 Other / unclassified 600 mg
Subject Coenzyme Q10 Other / unclassified 1200 mg

Indications